Last reviewed · How we verify
CLL-1.CAR T cells
At a glance
| Generic name | CLL-1.CAR T cells |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia (PHASE1)
- Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NA)
- Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML (EARLY_PHASE1)
- Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS (PHASE1, PHASE2)
- CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia (EARLY_PHASE1)
- A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLL-1.CAR T cells CI brief — competitive landscape report
- CLL-1.CAR T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI